Lexaria Bioscience Corp.

87 articles about Lexaria Bioscience Corp.

• Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

  7/22/2021

  Lexaria Bioscience Corp. is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.

• Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

  7/21/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.

• Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

  7/15/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada's premier federally funded research organization, the National Research Council.

• Lexaria Receives Patent Protection in Japan

  7/13/2021

  Lexaria Bioscience Corp. announces an additional expansion of its intellectual property portfolio with its first-ever patent granted in Japan.

• Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

  7/5/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange.

• Lexaria Announces 2021 Annual Meeting Results

  6/29/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting.

• Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

  6/15/2021

  Lexaria Bioscience Corp. is pleased to announce positive results from its tolerability and pharmacokinetic animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine.

• Lexaria Provides Progress Report on Six R&D Programs

  6/9/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development program.

• Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

  6/7/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study have been completed ahead of schedule.

• Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

  6/3/2021

  Lexaria Bioscience Corp. a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3.

• Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

  5/20/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH™ 2.0" cannabidiol formulations in its second 2021 applied research and development study program, HYPER-A21-2.

• Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

  5/12/2021

  Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India.

• Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

  5/6/2021

  Lexaria Bioscience Corp. a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs.

• Lexaria Commences Human Clinical Hypertension Study

  4/22/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway.

• Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants

  4/15/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consultants.

• Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network

  4/14/2021

  Lexaria Bioscience Corp. announced that its corporate client Amari Corp.'s "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network

• Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets

  4/6/2021

  Lexaria Bioscience Corp. a global innovator in drug delivery platforms, will begin important new applied research and development study programs planned in 2021.

• Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages

  3/24/2021

  DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexarias Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing

• Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET

  3/23/2021

  Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that CEO Chris Bunka is presenting at the Benzinga Biotech Small Cap Conference to be held on March 24-25, 2021.

• Lexaria's Antiviral Drug Evaluation Program Progressing

  3/16/2021

  Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.